EUVIMEDEUVIMED entdecken
Crossref

Folate‐PEG‐PROTAC Micelles for Enhancing Tumor‐Specific Targeting Proteolysis In Vivo

Junhui Ma, Lei Fang, Zhengjun Sun, Meijing Li, Ting Fan, Guangya Xiang, Xiang Ma iD

Advanced Healthcare Materials · 2024-08 · 13 (20)

DOI: 10.1002/adhm.202400109 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 03.05.2024. Verfasst von Junhui Ma und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. Hauptthemen laut MEDLINE: Micelles, Folic Acid, Polyethylene Glycols, Proteolysis. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Natural Science Foundation of China, Guizhou Provincial Science and Technology Support Plan, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Proteolysis targeting chimeras (PROTACs) technology is rapidly developed as a novel and selective medicinal strategy for the degradation of cellular proteins in cancer therapy. However, the applications of PROTACs as heterobifunctional molecules are largely limited by high molecular weight, low bioavailability, poor permeability, insufficient targeting, and low efficacy in vivo. Herein, self‐assembling micelles of FA‐PEG‐PROTAC are designed for cancer cell selective targeting and reductive‐response proteolysis in tumor‐bearing mice. FA‐PEG‐PROTAC is prepared by conjugating folic acid (FA)‐PEG with EGFR‐targeting PROTAC via a disulfide bond. The FA‐PEG‐PROTAC micelles, formed by self‐assembling, are demonstrated to significantly improve tumor targeting efficacy and exhibit excellent anti‐tumor efficacy in the mouse xenograft model compared to the traditional PROTACs. The strategy of applying self‐assembled FA‐PEG‐PROTAC micelles in tumor therapy can not only improve targeted proteolysis efficiency but also broaden applications in the development of PROTAC‐based drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicellesFolic AcidPolyethylene GlycolsProteolysisAnimalsHumansMiceCell Line, TumorMice, NudeXenograft Model Antitumor AssaysMice, Inbred BALB CErbB ReceptorsNeoplasmsDrug Delivery Systems

Stichwörter der Autor:innen

EGFRFolate‐PEG‐PROTACin vivomicellestargeting proteolysis

Substanzen

MicellesFolic AcidPolyethylene Glycolspoly(ethylene glycol)-folateErbB Receptors

Autor:innen und Institutionen

  • Department of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
  • Department of Pharmacy, Tongren Polytechnic College, Tongren, 554300, China.
  • Institute of the Higher Education Edible and Medicinal Fungi Engineering Research Center, Tongren, 554300, China.

ORCID-Profile: Xiang Ma

Förderung

  • Natural Science Foundation of China
  • Guizhou Provincial Science and Technology Support Plan
  • National Natural Science Foundation of China

Zitieren

APA

Ma, J., Fang, L., Sun, Z., Li, M., Fan, T., Xiang, G., & Ma, X. (2024). Folate‐PEG‐PROTAC Micelles for Enhancing Tumor‐Specific Targeting Proteolysis In Vivo. Advanced Healthcare Materials, 13(20). https://doi.org/10.1002/adhm.202400109

Vancouver

Ma J, Fang L, Sun Z, Li M, Fan T, Xiang G, et al. Folate‐PEG‐PROTAC Micelles for Enhancing Tumor‐Specific Targeting Proteolysis In Vivo. Advanced Healthcare Materials. 2024;13(20). doi:10.1002/adhm.202400109

BibTeX
@article{Ma2024,
  author = {Ma, Junhui and Fang, Lei and Sun, Zhengjun and Li, Meijing and Fan, Ting and Xiang, Guangya and Ma, Xiang},
  title = {Folate‐PEG‐PROTAC Micelles for Enhancing Tumor‐Specific Targeting Proteolysis In Vivo},
  journal = {Advanced Healthcare Materials},
  year = {2024},
  volume = {13},
  number = {20},
  doi = {10.1002/adhm.202400109}
}
Kostenlos starten →